Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Maintains $136 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $136.
August 22, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Neurocrine Biosciences and maintained a price target of $136.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Neurocrine Biosciences. The maintained price target of $136 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100